Patient enrollment is complete in a Phase 2a clinical trial testing Tiziana Life Sciences‘ foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS), a form of multiple sclerosis (MS) with limited treatment options. “Reaching full enrollment in this landmark study is a testament to the strong belief in foralumab’s potential and the urgent need […]

The post Trial of foralumab nasal spray for nonactive SPMS fills up appeared first on Multiple Sclerosis News Today.

Source: multiplesclerosisnewstoday.com